ANGO - Earnings call transcript Q2 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to the AngioDynamics Second Quarter Fiscal Year 2019 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions].

As a reminder, this conference call is being recorded. second is crossed website. available detailing this wire release and morning on news quarter the results earlier The the company’s conference of being at also www.angiodynamics.com. call over This Internet the broadcast the company’s the live section website at Investors is of webcast will call site replay the end of be after one hour And the at today’s same the the available approximately call.

for in now offering available company’s AngioDynamics’ conjunction to over Officer. statements. the from Presentations. press you regarding SEC, like may call, materially forward-looking actual future results release past A be the I’d during the or This including differ this Investors conference the company’s XXXX. identify results Before expected presentation the on results XX-Q will fiscal package earnings slide that the forward-looking company’s including the the revenue, cause and we course financial and of the should limitation, section operating those which financial turn year website flow that Forms Mr. company’s to events, Management listeners statements during President Clemmer, in the begin, and to under the the this review factors Chief conference to Clemmer? statements call. about company’s Jim performance call free to events caution I morning’s projections without company would with and with make or adjusted of and encourages into future filings discussing is XX-K, described the like read Executive insight specific cash also

Jim Clemmer

the second the earnings is to After With of XXXX for thank joining me of we’ll Good on your for Melissa. AngioDynamics’ us Officer. quarter Vice Michael and I open then today a will and provide financial brief quarter. highlights call our Executive Greiner, and that, you, fiscal financial detailed call provide President Thank a guidance. analysis Chief Today, AngioDynamics’ the Michael call. overview for performance the operating everyone, XXXX will fiscal our Financial you questions. morning,

operating We portfolio. to excellence, profitable with the during a second product cohesive our our operational are accomplishments and pleased and quarter, to market-leading ongoing reflect which building commitment growth, financial

second increased $XX.X Our by oncology, fiscal as for Vascular Interventions X.X% businesses. double-digit of as across Access quarter to improvement XXXX a million, our and the net well driven better-than-expected Therapies growth and sales Vascular in

and portfolio AngioVac, and slower our of margins, to the Additionally, recent and oncology. our optimization pleased to and core our financial Management, our goals Insufficiency gross headwinds RadiaDyne anticipated report our acquisitions our proposition growth At Overall, ablation enhancing business NanoKnife, product during improved contributing our product. results of Fluid results, fiscal supportive peripheral quarter line the sales for solid units, our in are level, profitability product business BioSentry Venous momentum, and these to expanded we within growth our continued radiofrequency value XXXX. and validating strategy each across are the offsetting and are of of generate

and Interventions in offset the an performance of Management by anticipated strong in business product each Now Insufficiency our Vascular or AngioVac our X.X% Therapies, partially decline growth was as year-over-year Venous focusing and on lines of Fluid the VIT businesses, grew business. the

the see Venous to encouraged were we However, declines in decelerating.

AngioVac double-digit quarter with for strong, technology. our our by work fiscal the of year. ease end procedural expect remained unique fifth and volume procedures to increasing year-over-year believe XX% our of second continue our to this volume, diligently back-half which growth we We procedural consecutive stabilize to quarter, validates comps the in in representing business

also identifying opportunities, to around a thrombus portfolio, targeted build while investments R&D AngioVac as we our management technology. our out making As noted previously, we growth franchise seek external are in

our related with in in our discuss we’ll plans growth the which and space. provide associated widely Conference, as continued the continued year. beginning at trusted and aim strong products by sales due a saw performance JPMorgan to more combination decline angiographic to during our core we the revenue at of our slightly restructuring products, of force that of offering opportunity, we week up technology sales We comprehensive second detail of Access our sales growth in thrombus peripheral midlines Next management combined the quarter, Vascular offset more PICCs. in to includes our catheters the execution sales implemented fiscal in as was improved X.X% was Dialysis of with Ports strong

thrombus Our market market-leading adoption BioFlo, Vascular reduction driven of our growth the continued Access technology. by was

and Dialysis sales attribute months, growth over which consistent We much have we’ve marketing this in While pleased changes We the particularly with products. VA, saw our resulted to of of of anticipate stronger growth leadership our growth the all in the forward. and implemented continue, decelerating in XX we to and we’re continued PICCs decline expect past we discipline execution. Ports commercial and that declines going in geographies

were revenue reported, driven now growth global disposables. oncology from and our adoption our of increased momentum XX.X%, BioSentry which NanoKnife and year-over-year, strong XX.X% continue increasing and and we As capital technology. up sales see includes RadiaDyne, by both in business, to

within previously – our around complement technologies As in our that with is continuum our built products The our our commitments existing platform ablative is core these with the how with addition to with we’ve a noted, consistent our of success our are oncology business these progressing signs seen as early line portfolio. acquisitions already both of care pleased we of platforms, expectations. of oncology build and are

the next We JPMorgan our outline will Conference. further our plans oncology at and platform growth week

a to obtaining wanted cancer you progress NanoKnife. towards indication our for We pancreatic also update on

are submitting process few to the final the final from of FDA. are the questions what in we responses We believe

IDE be this to step in expect We the our process towards final approval.

that reimbursement. pancreatic resolved. from This System demonstrates been around their treatment provided We Stage has of eligible effectiveness is questions and also the This Phase initial that III will positive received means significant Category that a have related treatment FDA a and receive study B determined will a study information for pancreatic the the device the comprehensive for determination NanoKnife safety of III NanoKnife as the cancer cancer the the be designation. that FDA for during the we

are to comprehensive benefits We demonstrate patients. technology’s study pancreatic capabilities President the Officer. that call Executive that, and cancer the this and turn to I’ll Greiner, With looking to Vice Chief will unique Financial our forward over Michael

Michael Greiner

good and Jim, Thanks, morning, everyone.

most were fiscal note the like that X.X%, are and Jim an mentioned which As quarter our our categories, product of X.X% the net we XXXX sales growth slides acquisitions mentioned, in on experienced documented solid million, year-over-year our representing second and to I’d for RadiaDyne BioSentry including also on growth of basis. previously. organic $XX.X of growth

gross ago. basis our margin expanded continued of Our is from strategy. XX.X% for optimization associated a operational year positive fiscal quarter on XXX impacts focus and the our as chain with reflecting XX.X% This to improvements portfolio supply well second XXXX as points

second Our gross margin our line expectations. quarter with was in

However, margin the with freight be gross that year, exceeding given and XX%, improvements to realized XX%. anticipate current we quarter will full-year the as be continued our fiscal now related headwinds XX% of to XXXX the gross to margin fourth in range well XXXX not in shipping, as productivity year

during of quarter, R&D $X.X spend we compared quarter uptick of Our fiscal Consistent research were during $X.X seen a in million, the to a of fiscal comments have an spend development million expenses acquisitions fiscal ago. as with XXXX second XXXX last and anticipate percentage supporting now quarter year – our approximately to and We net or sales spending million the study for of fiscal between $XX.X X% sales. NanoKnife this This recent contemplates our be this million, $XX.X year. to additional R&D of ad year. related back-half

down approximately expense of statement. of Moving SG&A XX% to year, the as expense $XX.X a percent We to to revenue the of XXXX million $X two be of compared a $XX.X approximately increase SG&A for the fiscal to second as which million, year. acquisitions. contemplates for back-half anticipate increased an the last million fiscal result of income quarter

second in adjusted last the income $X.X year. or reported compared year post the second in reform $X.XX the now updated share, is fiscal Our net last in million, the was XX.XX%. is was or income second was flow year, fiscal activities million. per quarter the net activities in fiscal Adjusted per of sales tax quarter our adjusted noted million statutory share for in income adjusted previously shown $X.X the rate. rate share margins. and quarter comparable cash second $X.X then we second quarter reported second compared enacted $X.XX to XX% greater on the XX% of the the EBITDAS the million, blended of XXXX, attributable quarter, operating increase of XXXX, and quarter of than items per for of in This In second operating improved fiscal the $X.XX Last growth had from XXXX. of the to free at or we $XX.X million, quarter tax based $XX.X to of net of XXXX The generated million, our $XX cash million table excluding gross presentation, and in reconciliation $XX.X

the to turning balance sheet. Now

we XXXX, million impact debt, cash had equivalents in million excluding deferred $XX.X XX, in November cash of financing $XXX of As and the and costs.

X.XX our ratio is debt times. As a EBITDAS net to currently adjusted result,

fiscal reaffirming guidance Finally, financial for are XXXX. our we

$XXX BioSentry continue We revenue the net including and sales XXXX million acquisitions. the to $XXX RadiaDyne to range of the from expect in both million, incremental

that, and between free $X.XX, $XX and to to continue as between million. also With the for We million flow I will turn EPS $X.XX questions. $XX expect over call Melissa adjusted as cash well

Operator

Markets. first be Brett KeyBanc Thank [Operator Capital question-and-answer question. session. conducting Our line Please time, from question At you. Instructions] this with proceed your Fishbin a of with the we’ll comes

Brett Fishbin

belt if also M&A early just of oncology rest for additional wondering BioSentry some was then RadiaDyne have that you now your the you deals and platform, could on few year, provide the into the the under commentary a I guys. of Hey, outlook generally your around integration year? this and

Jim Clemmer

to aligned an been really, and Jim. gate. of to their of received BioSentry seen end my merged They Many this. And have and the getting folks, really, The companies have The Brett, quality on also really can employees. and the prior Hey, lucky. and the part culture success Angio acquired. the with important really the great in on our of acquisitions folks cultures been joining we’re RadiaDyne out spent two we’ve I AngioDynamics the our of the to we’re acquisitive and and quality really were be company two by challenge, career pleased capability, companies a prior the of times, it’s morning. Good well we

Angio haven’t Now exciting oncology oncology In today, weeks sales we full from is all former will first and on sales sell products said, to our comes our how new time, for for trained our us vice learn team will versa and yet folks for products. The really be thing the these the other the marketing BioSentry and everybody and and two being that people. that, the cross-trained. together NanoKnife RadiaDyne even Solero and force

really really, we’re So excited.

So out making as M&A could to We’ve risk of hard We of risk all done make to lower sure the very has gate. these we’ve the deals out we to deal the gate, we think matter. company every make our opportunity and looked so prior know.

hurdles and of process challenges we have complete integration great. gate, been our company We the has like out it’s any as

as the your question our strategy. second-half of M&A to Now

we’ve As ago. so, balance a about or we’ve told minute talked really you a strong a now that for company sheet with the year-and-a-half Michael last built

have and a do to free this combination flow ratio the deals other capability We debt the in to cash space. due of good

financial look we’ve probably so. capability the going people we’re that to we to highlighted think, the have do to for areas opportunities, and I

to with spaces. trying to the the in just these win now market We’re right technology match available our opportunity

generating to of excited blend question. think for to in. we’re out the line. our internal new forward technologies product Thanks our of the We for things a development our add new going things research will own AngioDynamics and house So and more be growth coming

Brett Fishbin

with Thank around a case, ask shutdown? if positive on a the plan, could like was have, one around definitely of I it progress just any discussions sense on if And that’s just sounds not if impact from potential more government the the And agreement? the there the there then has NanoKnife wondering front. I general you development that you. if FDA ongoing has some just been timeline been the

Jim Clemmer

we’ll General our So Counsel, questions. have Trowbridge, take to your Steve

Stephen Trowbridge

Brett, Hey, the thanks for question.

on this been We to working in our IDE. have the continued will to to FDA have any, what our if shutdown closely get impact, try to for try been we’ve discussions and contacts our approved monitoring with understand that

reviewing and are Our agency sit that is move best there IDEs are who we information as to folks today forward. are -- -- are the are in continuing throughout the questions, taking working comments,

to as government what’s move being think, the to remains be that the said, both hope and out figure can outside we that inside means We this a on. shutdown at That expected the goes expedited what forward it that’s are trying exactly case. and happen going pace. case, We everybody to to I continue so going pretty

So we’re monitoring it.

conversations. It we folks need their hope seems that continues. We’re are having that we in the seats like and

Jim Clemmer

make only I’ll we can control We what one control. final can point.

this. hired in people a can So now in AngioDynamics, last world we like helped our PMA much the have XX really us is and the what control, participate can’t people government and for shutdown worry The submission. is themselves these now control the in Things really really, become the quality beyond really, company will world-class that are about doing our months that. have should important spaces IDE out. can of that What’s good work we we’ve an too and

for based the excited believe of the data product put we that quality submission this We our the very are an we upon opportunity. we’ll and forth. approval get and So

So then getting we’re care centers our of want the and an patients to a to progress. access forward part allowing to our registry looking the that monitor approval and to through be physicians gain care

hard really really things control can fashion. really, that worked in the to we’ve a we good So

will the FDA getting we question. care the soon. government itself, and So positive from hopefully look outcome the real to for from Thanks of take here, here forward a

Operator

Thank you.

the question. line Jason with Canaccord from comes Genuity. your question Please next Mills Our with of proceed

Jason Mills

for and hear question. Jim you me Can Hi, okay? thanks Mike, the taking

Jim Clemmer

Jason. Yes. morning, Good

Michael Greiner

Good morning.

Jason Mills

ratios respect you to Great. be and along? might your comes are if the Mike, willing taking with comfortable starting publicly guess, them where What about debt with right deal to I you. you talk

Michael Greiner

Yes, Jason. fair question,

by So as really under. those and we’ve got we feel mentioned, acquisitions which two in sought they’re Jim – just our diligence process went now. and out, about belt we’re We under the good a

to continue approach. that keep disciplined we’ll So

make a in a said, sense then period current one comfortable over be of So that go willing for X.X debt-to-EBITDA we a and currently us announce capital our time. the the to right go X.XX from an facility period in times, structure us – net being for the we allows that up will ratio. from pay don’t to our to and X That have near-term. opportunities, is anything times standpoint but to somewhere down appropriate over zone

we of M&A gotten two finish we would think talking opportunity. you’ve we And the remains and better be for XX we’ve going But the will months. format I for to been be is for right the right currently over digesting. I the about line, seen additional a have. But X think as seen, only ones that what part comfortable temporary we’ve something in timing over or feel temporary one

Jason Mills

Mike. sales selling where standpoint, fit you within that ultimately up require that force specialists? relates not current And might own its following or the as necessitate would what talk clinical to if it as own your you the on and AngioVac or well just also might how about or of arterial the whether to the product-related market from infrastructure, you various or a clinical from good. standpoint, time obtain both the that Thank at as into be dedicated Jim. Sounds a over time, then product look venous sort for evidence longer-term What questions, you, a the there? Thanks, plans existing you market I question And look last over on sales addresses of That’s its sales helpful. big address segments few strategy guess, a have question. be evidence a guys. seek NanoKnife to even opportunity really market might large you similar Can might that to force force an the And whether side. enough and specialist?

Jim Clemmer

Okay.

questions, good set So of Jason.

things. So a of couple

Let I’ll me the you sales start to side. asked. AngioVac first question start on the

year So split back for I’m sales – – June we communicated January VIT X I that in sorry, fiscal we group. think in our we XXXX, force our X, the

people that products, of – people catheter Catheter. our set a those and just have as AngioVac now core as both well the from a we of So the carry Angiographic

there their specialize between the I me products room we add more physicians, add the the gave At And away where clot-only and time, probably Venous make. from did. Over more have so and we’ll mentioned, the right high-end this them acuity of decisions Uni-Fuse We’ll the you’re we on on with Jason, them, some split we probably technology. will AngioVac when to have do to technologies. or to we we’ll when just new offering clinical thrombus getting point, lower-end force. get So as sales products Insufficiency bridge technologies a we cross that

communicated the R&D question, ongoing your continue we’ve think, done. we of I part AngioVac to Now have being that work other

to help from will another to more XX product in the version of get still believe come new the physicians to have follow indication. a expect they to areas the venous out here, iteration it XX the in there, And like months format, a PE that work about use easier structure. after to get which a device launch that, to which summer, AngioVac we’re us change We within of then this work then doing size allow it we may and for to the necessary we do will months

So we’re internally. still – on these we working things are

along make M&A, and any really made, thrombus changes an what we’ll that will that force And clot it really be But then very we our in very, be way, care, we new to that and after need really, believe market We’re more it’s believe bring offerings And important make again the R&D can going physician-friendly to portfolio. AngioVac we’ll yet. we to technology it’s that area. clot do as sales to expanded not ready then sure important we’ll with for from important our through a have make expand us. efforts a

marketing really good and have selling really communicating our what fortunate now to in We’re effective teams really can at products a do.

question switch I the there well as two coming the weeks, the mentioned asked training you people and to we’re and the thing along over BioSentry on doing a as we ago, ablation we’re our RadiaDyne, core forces same Now sales call. together, In have NanoKnife minute our our products.

really specialists also we the of approach our to time, after clinician want talk to to work make along to the And can time, opportunities fairs our the on approach. that Over oncology to other take with. also for we’ll physician goal more the in you week a means our registry-based you necessary selling the the more organ other that and partners that you partners about ready our way, and to over think We timeline organs get use similar cancer spring to ball to first, new care NanoKnife communicate and even the medical to products. hope we and that sure indication we want us marketing get done and communicate and you think we with FDA team all NanoKnife pancreatic talk match we’ll go think we’ll efforts we of But of effectiveness then next global expand approach and that and layout completely what we over other have we how Jason, treatment. a have we’ll for our

Jason Mills

Jim. Thanks, Thanks, Mike.

Jim Clemmer

Thank you.

Michael Greiner

Jason. Thanks,

Operator

you. Thank

the from next comes your Please Raymond Bedford Our James. with question. of with question Jayson proceed line

Jayson Bedford

in B timeline the Good starting of the with questions and the for happy New Category A I anyway? the just designation Year, you. does or morning, NanoKnife, change guess, trial guys. few structure

Jim Clemmer

Steve in. let’s Jayson, chime hi,

Stephen Trowbridge

Jayson. No, timeline designation B Category or the doesn’t projected change structure. Hi, our

that putting along the designation fact, come aimed this Category together getting strategy were that. we at and with benefits B all In a

last patients, get proper Category B reimbursement. pathway then as regulatory our move was you to study well plan take focus customers, our provide to to piece just around comprehensive as to back, a us provide into physicians, for step data generation a that to the really coverage So meaningful that’s tied and of provide to going this us a designation to remember creating The reimbursement. bow data primary

NanoKnife. the what then we third DRG from the codes the highest remember is talked for talked mapped about then are you B We into that we So And those provides codes receiving the of think where paying coverage. perspective specific the this a previously about leg DRGs. DRGs, right stool, ICD-XX Category into which

the comprehensive for study. are who now using reimbursement have our – treated me, excuse So opportunity within study our will get patients reimbursement will their customers or to product be the within

of does strategy well it this itself lend overall a to registry and broad-based So create very meaningful collect our to platform really data. using

Jayson Bedford

Okay.

approval reimbursed. for basically, what a get was, participants risk the you’re get So study, but there was saying that wouldn’t you’d

So B this now reimbursement Cat effectively you designation? have with

Michael Greiner

That’s correct.

Jayson Bedford

expected be patients each Okay. in Is XXX to trial the still arm?

Michael Greiner

get this of the crossing on that we’re right? some is of the to t’s i’s take, or that. of final with the doing now Give and the So right final FDA dotting little the to details

where you looking treated and going where I patients then at who those that comprehensive measuring that’s for that, think be without patients large compare what is – a to with to get benefit be. to it’s trial NanoKnife probably correct, we’re are like treated opportunity that what outcome survival pretty NanoKnife to the

around right probably you sides of. should that’s So think the

Jayson Bedford

topic. then this And last one on Okay.

Just for data label from the pancreatic clarity, approval trial, on ultimate the data the based from will on it direct based collect? registry data that be you be for or would the

Michael Greiner

and of two are are the one Those those same.

study has with to it that that that to trial doing registry-based a again, comprehensive direct provide comprehensive is some platform the data. the we’re there’s So RCT embedded

of you things. those shouldn’t several think So two

ultimate the provide upon evidence as full approval the body we see will be of for based to regulators. able the it So we’re that

Jayson Bedford

you. thank Okay,

or line up flattish high type of this the growth of sustainability and kind of product that, of either in more to market for seems mix The questions. couple Fluid of about Just price on and a growth maybe Management one. is you just Fluid congrats that Management? X% portfolio in the maybe seems contribution Can talk a high but effectively

Jim Clemmer

Jim. it’s Jayson, Hey,

because NAMIC challenging love I business to job good really and Management investor a brand, ago, many run. treating about do we us, Fluid we They giving our them got the customers about It’s a great job. you do we how a are because the It’s think talked want. to SKUs love community a in what I platform they differently. a year-and-a-half bit

a NAMIC So year-and-a-half reduced some a changes. I our we’re raised We talked couple raise We we by to I business working to SKUs we brand. think in do what made we many got still competitors some in areas is some or do is but operational to efficiency. We’ve what you one prices a of two unique. more. ago is and found And value that out the NAMIC well-trusted there, good

back people have to products We love great really the [indiscernible] going that and trust.

So I efficiencies think selling business what service and can quality our pull a marketing you by this see of team quality well. run out we combination tough great really infrastructure of right and of now really then is like make operational the have a and that products, the our good a supported

put AngioDynamics, well-run. crown So decide something a we what our what has and our and we how businesses Over it’s we we of be. of need jewels we when results been efforts well-managed, example, think towards one them, should be the great but time, can to manage this

Jayson Bedford

sustainability? the And

Jim Clemmer

hang know don’t on number. if a Long-term, seven I I’d

I always think, a Jayson, we’re fair market. that guys strong probably we’ll a don’t seven you’re outperforming the of business. question. We’ll know We way. you the I handle not market We’ve a keep outperform really guided the on know that, the asking if way. strength in in

outperform but well, we will to starting just always believe performing market. We’re it the really

Jayson Bedford

the drove of faster, But gains? was geography think, last the comp-related. and market, I then questioning is realize on than similar for some that Dialysis? What I is growth maybe And strength and all Vascular type there line Dialysis Access. me it really growth there? high new Was a of Ports clearly in is due share to Okay. Ports, single-digit

Jim Clemmer

some a we’ve good good really The OUS. VA. Externally, good has really question, the there two things. OUS job team a in It’s a Yes. Business. so done job done of

best So Again, benefits the there’s technology. core as in keep driving know we’ve the well. our some of on catheters. we We geographic had we BioFlo growth U.S. the make

challenge We PICCs get into We that. have them hands. a know people’s about with to

we’ll we products join experienced technology, had good us have in growth new Dialysis, of weren’t sold good marketing like we really Ports people us have and great at and ago. now have is manner in our combination these good a people that that the of couple If a and our I to experienced. can that look our really years this customers selling you as a maybe effectiveness see then And think, communicate of categories. well at we the team back technology for other We really to those companies this with products getting our specific and

Stephen Trowbridge

double just Jayson, there. Both this BioFlo more non-BioFlo both add both quarter least a at in are Dialysis categories Ports for little BioFlo and And with growing. detail and digits. growing

Jayson Bedford

I’ll queue. Thanks. right. All get in back

Jim Clemmer

Sure.

Operator

Thank you. line Please [Operator Group. comes proceed Craig-Hallum Matthew Instructions] question. Our final with of Hewitt question from your the with

Matthew Hewitt

Good quarter. morning. Congratulations on the strong

Jim Clemmer

morning, Matt. Good Thanks, Matt.

Matthew Hewitt

Just one me. for

adding in once kind remarks to speed? mentioned up are you your that think, you What and up soon. of I growth do be the that they prepared anticipate RadiaDyne BioSentry teams would cross-trained here coming

Jim Clemmer

our Michael Matt, FY Jim. – outlook XXXX it’s do We’ll earlier. reiterated for

our But of bit of guidance. a aspect take and what to when we But when an sales we’re we’ll continue when and we’re guidance the revenue. So event you to XXXX we’ve our around for aligned happens, we force like And lot clarity get going gave at time, XXXX the anything, of you more have. give and give trading prior see you, we look time little for these of it’ll trained, can done range you to probably I more pre-training think effect you’ll over people. a we fully holding too the

kind we months. few even we’ll the We’ve our gave out But we’re geographies, each have we first that we funny think some a of doing new long-term already gate effect you new effect stronger managers, of technologies teams have already But didn’t coming if reps these fortunate the an together. see wouldn’t year and to of the good in effectiveness of really we be three it’s new this much don’t people, and of wait have seen to current a We really communicate so right think this in minute. that “Oh, fiscal sales guidance. we’ll say,

about me that, and that’s radiation those about to let’s talk can you I monitoring talk really that. interesting, therapy. hear Now system symmetry

a going we’re two are weeks BioSentry and really, had think going AngioDynamics, U.S., they’re now base have crossover now to and the good I our as well. we’re So And by we to effect the in really sales and bringing sell from AngioDynamics products XX people have those to about of going to in RadiaDyne people. in going portfolio XX of even the ablation have people

Michael any So going move what gave but we’re this excited, to other guidance beyond really we’re not you morning.

Matthew Hewitt

much. All you Understood. Thank very right.

Operator

I’ll to question-and-answer And our Mr. session. floor Clemmer the that for you. comments. any turn concludes final Thank back

Jim Clemmer

you Thank today. us for joining

indicative I put we results growth free which drop how out also a our to today. that through to effectiveness profitable They’re cash our flow proud generate high-level good is efficiency returns. perform, and can consistent to manner and and growth company expects of of a has are these that strong think, company

changing. get patients and us. with company the care we’re to in by What’s we’re for a share capabilities capability is can sleeves products. combination to do building stronger also The of and able you the and of new calls, a those delivered roll really products, can which for AngioDynamics of AngioDynamics quality this work to and and the lot them things us, that who culture, of of these below quality added lot willingness our the the the important goes with we’ve to people year-and-a-half technology so, and hard of quality people by of the but of their to culture the a We’re people. a better accountability up our or on we our our last joining People high-level

you So and to you us in We’ll we’re work joining few months, really for today. thank hard. a proud to talk

Operator

concludes you. teleconference. Thank This today’s

your your disconnect at Thank for may time. You lines you participation. this

AngioDynamics (ANGO) 4 Jan 192019 Q2 Earnings call transcript